Comparing outcomes in renal replacement therapy: How should we correct for case mix?

被引:20
|
作者
Khan, IH
Campbell, MK
Catarovich, D
Catto, GRD
Delcroix, C
Edward, N
Fontenaille, C
van Hamersvelt, HW
Henderson, IS
Koene, RAP
Papadimitriou, M
Ritz, E
Ramsay, C
Tsakiris, D
MacLeod, AM
机构
[1] Univ Aberdeen, Dept Med & Therapeut, Aberdeen AB9 2ZD, Scotland
[2] Renal Unit, Aberdeen AB9 2ZD, Scotland
[3] Ninewells Hosp, Renal Unit, Dundee DD1 9SY, Scotland
[4] Univ Aberdeen, Hlth Serv Res Unit, Aberdeen, Scotland
[5] Univ Nantes, Nantes, France
[6] Acad Hosp, Nijmegen, Netherlands
[7] St Josef Hosp, Veldhoven, Netherlands
[8] Aristotelian Univ Salonika, GR-54006 Salonika, Greece
[9] Univ Heidelberg, Heidelberg, Germany
关键词
survival; ESRD; renal replacement therapy; dialysis; transplantation; case mix; risk groups;
D O I
10.1053/ajkd.1998.v31.pm9506684
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The need to evaluate the effectiveness of clinical practice to justify expensive therapy in the face of financial constraints in all areas of health care delivery makes it necessary to identify groups of patients who are likely to benefit most from treatment. Various risk stratification methods have been used for analyzing survival probabilities for patients receiving renal replacement therapy. Complicated risk stratification methods produce large numbers of risk groups of small sizes, which makes comparison between individual centers difficult. We compared three simple methods of risk stratification, that divided patients into low-, medium-, and high-risk groups, in a cohort of 1,407 patients who commenced renal replacement therapy in five European countries during a 7-year period. Method 1 considered age (>55 years) and diabetes alone; method 2 used a higher age limit (>70 years) and comorbid illnesses, including those other than diabetes; and method 3 used only the number of comorbidities (none, 1, or greater than or equal to 2) for stratification. Kaplan-Meier survival curves were constructed for comparison between risk groups and Cox's regression model used to assess strength of relationship with mortality. Although patient survival was significantly different between the low-, medium-, and high-risk groups using all three methods, Cox's regression analysis showed that method 2 provided the greatest discrimination between risk groups. In predicting mortality, method 2 (based on comorbidities and age) showed the highest sensitivity and specificity (84% and 80%, respectively) compared with method 1 (80% and 74%) and method 3 (64% and 82%). Validation of this approach in other populations in a prospective study is required before this method, which takes into account the influences of both age and comorbidity for risk stratification, can be used for comparing survival data and for presenting results of renal replacement therapy. (C) 1998 by the National Kidney Foundation, Inc.
引用
收藏
页码:473 / 478
页数:6
相关论文
共 50 条
  • [1] Comparing outcomes in renal replacement therapy: How should we correct for case mix? (vol 31, pg 473, 1998)
    Khan, IH
    Campbell, MK
    Cantarovich, D
    Catto, GRD
    Delcroix, C
    Edward, N
    Fontenaille, C
    van Hamersvelt, HW
    Henderson, IS
    Koene, RAP
    Papadimitriou, M
    Ritz, E
    Ramsay, C
    Tsakiris, D
    MacLeod, AM
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (05) : 900 - 900
  • [2] Renal replacement therapy in the ICU: when should we STARRT?
    Bellomo, Rinaldo
    [J]. CRITICAL CARE AND RESUSCITATION, 2019, 21 (03) : 156 - 157
  • [3] Observational cohort of renal replacement therapy patients at a district general hospital ICU: case mix and outcomes
    C Hayes-Bradley
    S Caddel
    J Paddle
    [J]. Critical Care, 13 (Suppl 1):
  • [4] How should we monitor men receiving testosterone replacement therapy?
    Alsina, Manuel
    Anna, Leilani St.
    [J]. JOURNAL OF FAMILY PRACTICE, 2010, 59 (12): : 711 - 712
  • [5] How can we advance in renal replacement therapy techniques?
    Castro, Ana
    Neri, Mauro
    Karopadi, Akash Nayak
    Lorenzin, Anna
    Marchionna, Nicola
    Ronco, Claudio
    [J]. NEFROLOGIA, 2019, 39 (04): : 372 - 378
  • [6] Renal replacement therapy: how can we contain the costs?
    Vanholder, Raymond
    Van Biesen, Wim
    Lameire, Norbert
    [J]. LANCET, 2014, 383 (9931): : 1783 - 1785
  • [7] RENAL-FAILURE - RENAL REPLACEMENT THERAPY - PRACTICE, CASE-MIX, AND OUTCOME
    LOWRIE, EG
    [J]. LANCET, 1993, 341 (8842): : 412 - 413
  • [8] How to adjust for case-mix when comparing outcomes across healthcare providers
    Santhakumaran, Shalini
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD-EDUCATION AND PRACTICE EDITION, 2014, 99 (02): : 70 - 71
  • [9] Should we recommend nicotine replacement therapy?
    David, SP
    [J]. AMERICAN FAMILY PHYSICIAN, 2001, 63 (11) : 2245 - 2247
  • [10] Renal replacement therapy in the developing world: Are we on the right track, or should there be a new paradigm?
    Correa-Rotter, Ricardo
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (06): : 1635 - 1636